PDCD1 and cancer: For example, the specific gut microbiome of nivolumab and pembrolizumab responders was identified, while the synergistic effect of anti-PD-1 and B. bifidum strains reportedly reduced cancer growth by modulating the production of IFN- γ by intensifying biosynthesis of immune-stimulating metabolites [102,113].